BioCardia completes PMDA consultation for CardiAMP, advancing toward Japan marketing approval filing

BioCardia, Inc.

BioCardia (NASDAQ: BCDA) completed the PMDA consultation on application materials for its CardiAMP Cell Therapy System for ischemic heart failure in Japan.
CEO Peter Altman said the company is targeting treatment of first patients in Japan and realization of commercial revenues in 2028.
CardiAMP has been evaluated in three clinical trials involving more than 200 patient procedures, including two randomized, double-blind, placebo-controlled trials.
BioCardia cautioned that completion of the consultation does not constitute approval; CardiAMP remains subject to PMDA review and Japanese regulatory requirements.
The announcement came via press release dated November 6, 2026, furnished under Item 8.01 with Exhibit 99.1.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.